Cite
A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis.
MLA
Hong, Jin, et al. “A Prospective, Randomized Study of Toremifene vs. Tamoxifen for the Treatment of Premenopausal Breast Cancer: Safety and Genital Symptom Analysis.” BMC Cancer, vol. 20, no. 1, July 2020, pp. 1–10. EBSCOhost, https://doi.org/10.1186/s12885-020-07156-x.
APA
Hong, J., Huang, J., Shen, L., Zhu, S., Gao, W., Wu, J., Huang, O., He, J., Zhu, L., Chen, W., Li, Y., Chen, X., & Shen, K. (2020). A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis. BMC Cancer, 20(1), 1–10. https://doi.org/10.1186/s12885-020-07156-x
Chicago
Hong, Jin, Jiahui Huang, Lili Shen, Siji Zhu, Weiqi Gao, Jiayi Wu, Ou Huang, et al. 2020. “A Prospective, Randomized Study of Toremifene vs. Tamoxifen for the Treatment of Premenopausal Breast Cancer: Safety and Genital Symptom Analysis.” BMC Cancer 20 (1): 1–10. doi:10.1186/s12885-020-07156-x.